Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 673.50
Bid: 674.50
Ask: 675.00
Change: -2.00 (-0.30%)
Spread: 0.50 (0.074%)
Open: 676.00
High: 676.00
Low: 669.50
Prev. Close: 675.50
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

4 Oct 2013 07:00

4 October 2013 - Tate & Lyle PLC

Trading Update

Tate & Lyle issues the following trading update for the six months ended 30 September 2013 ahead of the announcement of Half Year Results on Thursday 7 November 2013.

OPERATING PERFORMANCE – CONTINUING OPERATIONS

The Group’s performance in the second quarter was broadly in line with our expectations. Adjusted1 operating profit for the Group for the first half is expected to be slightly lower than the comparative period, largely driven by softness in the US beverage sector as a result of the cold spring and slow start to the summer which has affected sweetener volumes in both divisions.

In Speciality Food Ingredients, volume growth is expected to be in line with the wider speciality food ingredients market with strong volume growth in emerging markets and Europe, partially offset by slightly lower volumes in the US. We saw strong demand for our texturant and fibre ingredients, particularly in Asia Pacific and Latin America, but softness in the US beverage sector held back volume growth across our higher margin speciality sweeteners. This, together with lower selling prices for SPLENDA® Sucralose, is expected to result in operating profit in this division being broadly in line with the prior year period in constant currency.

Within Bulk Ingredients, operating profit is expected to be somewhat lower than the comparative period driven by lower US bulk liquid sweetener volumes. During the second quarter, we largely mitigated the increased costs associated with poor end of season corn quality and resultant lower starch production yields, and the significant decrease in the corn price.

OUTLOOK

In Speciality Food Ingredients, we expect to deliver growth in volumes, sales and profits across all regions for the full year.

Within Bulk Ingredients, in North America we expect solid demand for liquid sweeteners and stable demand for our other products. In Europe, lower corn prices are expected to more than offset the impact of lower sugar prices on isoglucose margins. Consequently, we anticipate this division delivering a stronger performance during the second half than the same period last year, and full year profits to be more evenly distributed between the first and second half.

Our profits remain sensitive to fluctuations in foreign currency particularly the US dollar to sterling exchange rate. In addition, as usual, the outcome of the calendar year sweetener pricing rounds will influence performance in the final quarter of the financial year.

Overall, we expect to deliver another year of profitable growth.

1 Continuing operations: before exceptional items and amortisation of intangible assets acquired through business combinations

END

A conference call will be held today at 8:00am BST, hosted by Javed Ahmed, Chief Executive and Tim Lodge, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666

Password: Tate & Lyle

UK replay number: +44 (0)20 8196 1998

International replay numbers:

http://www.meetingzone.com/en-GB/replaydialinnumbers.aspx

Replay access PIN: 3480340

A replay of this call will be available after the end of the live call for 14 days until 17 October 2013.

For more information contact Tate & Lyle PLC:

Mathew Wootton, Group VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7500 100 320

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 20 7269 7113 or Mobile: +44 (0) 7775 641 807

Copyright Business Wire 2013

Date   Source Headline
17th Jan 20222:00 pmRNSHolding(s) in Company
12th Jan 20224:00 pmRNSHolding(s) in Company
10th Jan 20223:45 pmRNSChange of Registered Office
10th Jan 20223:40 pmRNSDirector/PDMR Shareholding
4th Jan 20224:00 pmRNSBlock listing Interim Review
10th Dec 20212:09 pmRNSHolding(s) in Company
9th Dec 20213:10 pmRNSDirector/PDMR Shareholding
1st Dec 20219:58 amRNSTotal Voting Rights
18th Nov 20214:15 pmRNSHolding(s) in Company
5th Nov 202111:45 amRNSDirector/PDMR Shareholding
4th Nov 20217:00 amRNSHalf-year Report
3rd Nov 20216:01 pmRNSDirectorate Change
29th Oct 202111:15 amRNSHolding(s) in Company
21st Oct 20214:45 pmRNSRestatement re Primary Products Disposal
18th Oct 20212:30 pmRNSHolding(s) in Company
13th Oct 202112:30 pmRNSHolding(s) in Company
6th Oct 20213:30 pmRNSHolding(s) in Company
6th Oct 202111:15 amRNSDirector/PDMR Shareholding
4th Oct 20212:30 pmRNSDirector/PDMR Shareholding
4th Oct 20217:00 amRNSTotal Voting Rights
30th Sep 202112:00 pmRNSResult of General Meeting
13th Sep 20214:30 pmRNSCircular re. KPS Partnership
1st Sep 20219:58 amRNSTotal Voting Rights
18th Aug 202110:10 amRNSDirector/PDMR Shareholding
11th Aug 20214:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20213:15 pmRNSTotal Voting Rights
29th Jul 202112:45 pmRNSResult of AGM
23rd Jul 20215:00 pmRNSHolding(s) in Company
22nd Jul 20213:15 pmRNSDirector/PDMR Shareholding
16th Jul 20213:30 pmRNSHolding(s) in Company
12th Jul 20214:00 pmRNSHolding(s) in Company
12th Jul 20213:50 pmRNSHolding(s) in Company
12th Jul 20217:00 amRNSTate & Lyle to be re-positioned as growth business
8th Jul 20213:30 pmRNSHolding(s) in Company
8th Jul 20213:14 pmRNSHolding(s) in Company
1st Jul 20214:40 pmRNSBlock listing Interim Review
1st Jul 20214:38 pmRNSTotal Voting Rights
15th Jun 20212:15 pmRNSAnnual Financial Report
14th Jun 20212:05 pmRNSHolding(s) in Company
14th Jun 20212:00 pmRNSHolding(s) in Company
9th Jun 20213:49 pmRNSDirector/PDMR Shareholding
1st Jun 20212:34 pmRNSTotal Voting Rights
27th May 20217:00 amRNSFinal Results
4th May 202111:30 amRNSTotal Voting Rights
28th Apr 202110:00 amRNSDirectorate Change
26th Apr 20217:00 amRNSResponse to media speculation
13th Apr 20213:45 pmRNSHolding(s) in Company
1st Apr 202112:00 pmRNSTotal Voting Rights
25th Mar 202110:00 amRNSDirectorate Changes
23rd Mar 20213:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.